CUDC 427

Drug Profile

CUDC 427

Alternative Names: CUDC-427; GDC-0917; RG-7459

Latest Information Update: 27 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Amides; Antineoplastics; Oxazoles; Peptides; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 01 Apr 2016 Curis completes a phase I trial in Solid tumours and lymphomas (second-line therapy or greater; late stage disease) in USA
  • 06 Oct 2015 Phase-I development is ongoing for Solid tumours and Lymphomas in USA
  • 06 Oct 2015 CUDC 427 is available for licensing -http://www.curis.com/pipeline/cudc-427
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top